Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Dignass

Showing results (71-80 of 177) with videos related to

Pageof 18
Sort By:
Advances in Therapy|May 6, 2025
One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn's Disease: A Network Meta-AnalysisTim Disher, Dominik Naessens, Myrlene Sanon, et al.
BMJ Open Gastroenterology|May 31, 2016
Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort studySilvio Danese, Ailsa Hart, Axel Dignass, et al.
World Journal of Gastroenterology|January 27, 2006
Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitisWolfgang Kruis, Axel Dignass, Elisabeth Steinhagen-Thiessen, et al.
Journal of Gastroenterology|June 6, 2018
Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel diseaseStefan Schreiber, Axel Dignass, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|December 3, 2010
European evidenced-based consensus on reproduction in inflammatory bowel diseaseC Janneke van der Woude, Sanja Kolacek, Iris Dotan, et al.
Zeitschrift Fur Gastroenterologie|April 10, 2024
[Update: Addendum to S3-Guidelines Crohn disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease with regard to COVID-19 (version 2.0)]Carsten Schmidt, Andreas Stallmach, Andreas Sturm, et al.
Inflammatory Bowel Diseases|October 17, 2022
Impact of Crohn's Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysisJoana Roseira, Mafalda Santiago, Maria Manuela Estevinho, et al.
United European Gastroenterology Journal|January 29, 2025
Inadequate Therapy Response on Advanced Therapy in Ulcerative Colitis Adult Patients: A Retrospective Analysis of German Health Claims DataAxel Dignass, Irina Blumenstein, Carolina Schwedhelm, et al.
Inflammatory Bowel Diseases|July 31, 2024
Mucosal and Transmural Healing and Long-term Outcomes in Crohn's DiseaseBruce E Sands, Silvio Danese, J Casey Chapman, et al.
United European Gastroenterology Journal|November 9, 2019
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®<sup>MMX®</sup>) for active, mild-to-moderate ulcerative colitisSilvio Danese, Ailsa Hart, Axel Dignass, et al.
Pageof 18

Showing results (71-80 of 177) with videos related to

Sort By:
Pageof 18
Advances in Therapy|May 6, 2025
One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn's Disease: A Network Meta-AnalysisTim Disher, Dominik Naessens, Myrlene Sanon, et al.
BMJ Open Gastroenterology|May 31, 2016
Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort studySilvio Danese, Ailsa Hart, Axel Dignass, et al.
World Journal of Gastroenterology|January 27, 2006
Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitisWolfgang Kruis, Axel Dignass, Elisabeth Steinhagen-Thiessen, et al.
Journal of Gastroenterology|June 6, 2018
Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel diseaseStefan Schreiber, Axel Dignass, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|December 3, 2010
European evidenced-based consensus on reproduction in inflammatory bowel diseaseC Janneke van der Woude, Sanja Kolacek, Iris Dotan, et al.
Zeitschrift Fur Gastroenterologie|April 10, 2024
[Update: Addendum to S3-Guidelines Crohn disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease with regard to COVID-19 (version 2.0)]Carsten Schmidt, Andreas Stallmach, Andreas Sturm, et al.
Inflammatory Bowel Diseases|October 17, 2022
Impact of Crohn's Disease Therapies on Histology in Randomized Controlled Trials: Systematic Review With Meta-analysisJoana Roseira, Mafalda Santiago, Maria Manuela Estevinho, et al.
United European Gastroenterology Journal|January 29, 2025
Inadequate Therapy Response on Advanced Therapy in Ulcerative Colitis Adult Patients: A Retrospective Analysis of German Health Claims DataAxel Dignass, Irina Blumenstein, Carolina Schwedhelm, et al.
Inflammatory Bowel Diseases|July 31, 2024
Mucosal and Transmural Healing and Long-term Outcomes in Crohn's DiseaseBruce E Sands, Silvio Danese, J Casey Chapman, et al.
United European Gastroenterology Journal|November 9, 2019
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®<sup>MMX®</sup>) for active, mild-to-moderate ulcerative colitisSilvio Danese, Ailsa Hart, Axel Dignass, et al.
Pageof 18